SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 267 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $47 | -23.0% | 1,775 | 0.0% | 0.00% | – |
| Q1 2024 | $61 | +19.6% | 1,775 | 0.0% | 0.00% | – |
| Q4 2023 | $51 | +4.1% | 1,775 | 0.0% | 0.00% | – |
| Q3 2023 | $49 | -60.8% | 1,775 | -57.2% | 0.00% | -100.0% |
| Q2 2023 | $125 | -24.7% | 4,148 | -9.7% | 0.00% | 0.0% |
| Q1 2023 | $166 | +1.2% | 4,594 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $164 | +5.1% | 4,594 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $156 | +17.3% | 4,594 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $133 | -100.0% | 4,594 | -66.2% | 0.00% | -50.0% |
| Q4 2019 | $322,000 | -13.9% | 13,592 | 0.0% | 0.00% | -33.3% |
| Q3 2019 | $374,000 | -49.8% | 13,592 | -39.6% | 0.00% | -50.0% |
| Q2 2019 | $745,000 | -5.6% | 22,509 | 0.0% | 0.01% | 0.0% |
| Q1 2019 | $789,000 | +68.2% | 22,509 | +141.9% | 0.01% | +50.0% |
| Q3 2018 | $469,000 | -15.8% | 9,306 | 0.0% | 0.00% | -20.0% |
| Q2 2018 | $557,000 | -57.1% | 9,306 | -67.2% | 0.01% | -58.3% |
| Q1 2018 | $1,299,000 | +15.0% | 28,358 | 0.0% | 0.01% | +20.0% |
| Q4 2017 | $1,130,000 | -0.4% | 28,358 | 0.0% | 0.01% | 0.0% |
| Q3 2017 | $1,134,000 | -7.2% | 28,358 | 0.0% | 0.01% | -16.7% |
| Q2 2017 | $1,222,000 | – | 28,358 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 297,500 | $17,478,000 | 3.94% |
| ASHFORD CAPITAL MANAGEMENT INC | 1,124,405 | $36,341,000 | 3.91% |
| ARMISTICE CAPITAL, LLC | 3,100,000 | $100,192,000 | 1.94% |
| S&T BANK/PA | 316,326 | $10,224,000 | 1.54% |
| Bruce & Co., Inc. | 222,105 | $7,178,000 | 1.47% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 379,875 | $12,278,000 | 1.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 854,949 | $27,632,000 | 1.10% |
| Soleus Capital Management, L.P. | 251,000 | $8,112,000 | 1.05% |
| Parkman Healthcare Partners LLC | 108,954 | $3,521,000 | 1.03% |
| Aristotle Capital Boston, LLC | 1,258,067 | $40,661,000 | 1.03% |